Wenzhi Tan
Overview
Explore the profile of Wenzhi Tan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
1275
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guo Y, Sun Y, Li Z, Zuo C, Liu X, Chen Y, et al.
Int J Cancer
. 2024 Aug;
155(11):2080-2093.
PMID: 39129048
Bacteria are ideal anticancer agents and carriers due to their unique capabilities that are convenient in genetic manipulation, tumor-specific targeting, and deep-tissue penetration. However, the specific molecular mechanisms of bacteria-mediated...
2.
Liu J, He C, Tan W, Zheng J
Life Sci
. 2024 Jul;
352:122897.
PMID: 38971366
The major reason for the failure of conventional therapies is the heterogeneity and complexity of tumor microenvironments (TMEs). Many malignant tumors reprogram their surface antigens to evade the immune surveillance,...
3.
Tan W, Thiruppathi J, Hong S, Puth S, Pheng S, Mun B, et al.
NPJ Vaccines
. 2024 Jun;
9(1):121.
PMID: 38942773
No abstract available.
4.
Tan W, Thiruppathi J, Hong S, Puth S, Pheng S, Mun B, et al.
NPJ Vaccines
. 2024 Jun;
9(1):108.
PMID: 38879560
Alzheimer's disease (AD) and related tauopathies are associated with pathological tau protein aggregation, which plays an important role in neurofibrillary degeneration and dementia. Targeted immunotherapy to eliminate pathological tau aggregates...
5.
Sun Y, Guo Y, Liu X, Liu J, Sun H, Li Z, et al.
Theranostics
. 2023 Nov;
13(15):5546-5560.
PMID: 37908720
Attenuated VNP20009 has been used to treat tumor-bearing mice and entered phase I clinical trials. However, its mild anticancer effect in clinical trials may be related to insufficient bacterial colonization...
6.
Zhang Y, Tan W, Sultonova R, Nguyen D, Zheng J, You S, et al.
Biomaterials
. 2023 May;
298:122135.
PMID: 37148758
The use of appropriately designed immunotherapeutic bacteria is an appealing approach to tumor therapy because the bacteria specifically target tumor tissue and deliver therapeutic payloads. The present study describes the...
7.
Guo Y, Song M, Liu X, Chen Y, Xun Z, Sun Y, et al.
J Control Release
. 2022 Oct;
351:860-871.
PMID: 36181917
Genetically engineered bacterial cancer therapy presents several advantages over conventional therapies. However, the anticancer effects of bacterium-based therapies remain insufficient, and serious side effects may be incurred with the increase...
8.
Zhang Z, Mo Y, Wu L, Wang X, Liao G, Tan W, et al.
Anticancer Drugs
. 2022 Sep;
33(9):923-934.
PMID: 36136992
Previous studies have suggested that circular RNAs (circRNAs) are engaged in the progression of papillary thyroid carcinoma (PTC). However, the mechanism of circ_0002111 in PTC is still unclear. In this...
9.
Liu X, Guo Y, Sun Y, Chen Y, Tan W, Min J, et al.
Front Microbiol
. 2022 Jul;
13:914575.
PMID: 35847095
defective in guanosine 5'-diphosphate-3'-diphosphate (ppGpp) synthesis (ΔppGpp) is an attenuated strain with good biosafety and excellent anticancer efficacy. It has been widely applied in preclinical studies of anticancer therapy for...
10.
Puth S, Verma V, Hong S, Tan W, Lee S, Rhee J
Biomaterials
. 2022 May;
286:121542.
PMID: 35594837
Therapeutic cancer vaccines (TCVs) should induce robust tumor-specific T cell responses. To achieve this, TCVs incorporate T cell epitopes and strong adjuvants. Here, we report an all-in-one adjuvanted cancer vaccine...